

## Product

# Amundi S&P World Health Care Screened UCITS ETF Acc

A Sub-Fund of AMUNDI ETF ICAV

IE0006FM6MI8 - Currency: EUR

*This Sub-Fund is authorised in Ireland.*

*Management Company: Amundi Ireland Limited (thereafter: "we"), a member of the Amundi Group of companies, is authorised in Ireland and regulated by the Central Bank of Ireland.*

*The CBI is responsible for supervising Amundi Ireland Limited in relation to this Key Information Document.*

*For more information, please refer to [www.amundi.ie](http://www.amundi.ie) or call 01-4802000.*

*This document was published on 28/04/2026.*

## What is this product?

**Type:** Shares of a Sub-Fund of AMUNDI ETF ICAV, an Undertaking for Collective Investments in Transferable Securities (UCITS), established as an ICAV.

**Term:** The term of the Sub-Fund is unlimited. The Management Company may terminate the fund by liquidation or merger with another fund in accordance with legal requirements.

### Objectives:

The Sub-Fund is passively managed.

The objective of the Sub-Fund is to track the performance of the S&P World Health Care Weighted & Screened Index (the "Index"). The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund.

The Sub-Fund promotes environmental and/or social characteristics through among others, replicating an Index integrating an environmental, social and governance ("ESG") rating.

The Index is an equity index that measures the performance of eligible equity securities from the S&P World Health Care Index (the "Parent Index"). The Parent Index is designed to measure the performance of large and mid-cap health care companies in developed markets excluding Korea which make up approximately 85% of the total available capital. Health care companies are identified by reference to the GICS. The health care sector includes health care providers and services, companies that manufacture and distribute health care equipment and supplies, and health care technology companies. It also includes companies involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. The Index is selected and weighted to enhance ESG profiles, and reduce carbon emission intensity, all compared to the Parent Index. The Index applies several ESG filters (e.g. exclusions filters to exclude companies involved in controversial business activities (e.g. controversial weapon), or involved in ESG controversies) and optimization constraints (GHG intensity reduction and identical S&P Global ESG Score or improvement of such score compared to the Parent Index).

The Index is a net total return index, meaning that dividends net of tax paid by the index constituents are included in the Index return. More information about the composition of the Index and its operating rules are available in the prospectus and at

<https://www.spglobal.com/spdji/en/supplemental-data/europe>

The Index value is available via Bloomberg (SPDSEHUN).

The exposure to the Index will be achieved through a direct replication, mainly by making direct investments in transferable securities and/or other eligible assets representing the Index constituents in a proportion extremely close to their proportion in the Index.

The Investment Manager will be able to use derivatives in order to deal with inflows and outflows and which relate to the Index or constituents of the Index for investment and/or efficient portfolio management. In order to generate additional income to offset its costs, the Sub-Fund may also enter into securities lending operations.

**Intended Retail Investor:** This product is intended for investors, with a basic knowledge of and no or limited experience of investing in funds seeking to increase the value of their investment over the recommended holding period with the ability to bear losses up to the amount invested.

**Redemption and Dealing:** The Sub-Fund's shares are listed and traded on one or more stock exchanges. In normal circumstances, you may deal in shares during the trading hours of the stock exchanges. Only authorised participants (e.g., selected financial institutions) may deal in shares directly with the Sub-Fund on the primary market. Further details are provided in the AMUNDI ETF ICAV prospectus.

**Distribution policy:** As this is a non-distributing share class, investment income is reinvested. the accumulation share automatically retains, and re-invests, all attributable income within the Sub-Fund; thereby accumulating value in the price of the accumulation shares.

**More Information:** You may get further information about the Sub-Fund, including the prospectus, and financial reports which are available at and free of charge on request from: Amundi Ireland Limited at AMUNDI IRELAND LIMITED, One George's Quay Plaza, George's Quay, Dublin 2, Ireland.

The Net Asset Value of the Sub-Fund is available on [www.amundi.ie](http://www.amundi.ie)

**Depository:** HSBC Continental Europe.

**Representative in Switzerland:** CACEIS (Switzerland) SA, 35 Route de Signy, P.O. Box, 2259, CH-1260 Nyon .

**Paying agent in Switzerland:** CACEIS Bank, Montrouge, Nyon Branch/Switzerland, 35 Route de Signy, CH-1260 Nyon.

In Switzerland, the prospectus, the Key Information Document, the Articles of incorporation as well as the annual and semi-annual reports of this UCITS can be obtained, free of charge, from the representative in Switzerland.



## Investment EUR 10,000

Scenarios	If you exit after	
	1 year	5 years*
<b>Total Costs</b>	€24	€220
<b>Annual Cost Impact**</b>	0.2%	0.3%

\* Recommended holding period.

\*\* This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 12.21% before costs and 11.93% after costs.

We do not charge an entry fee

If you are invested in this product as part of an insurance contract, the costs shown do not include additional costs that you could potentially bear.

## COMPOSITION OF COSTS

One-off costs upon entry or exit		If you exit after 1 year
<b>Entry costs*</b>	We do not charge an entry fee for this product.	Up to 0 EUR
<b>Exit costs*</b>	We do not charge an exit fee for this product, but the person selling you the product may do so.	0.00 EUR
Ongoing costs taken each year		
<b>Management fees and other administrative or operating costs</b>	0.18% of the value of your investment per year. This percentage is based on actual costs over the last year.	18.00 EUR
<b>Transaction costs</b>	0.07% of the value of your investment per year. This is an estimate of the cost of buying and selling the underlying investments for the product. The actual amount depends on how much we buy and sell.	6.93 EUR
Incidental costs taken under specific conditions		
<b>Performance fees</b>	There is no performance fee for this product.	0.00 EUR

\* Secondary Market: because the Sub-Fund is an ETF, Investors who are not Authorized Participants will generally only be able to buy or sell shares on the secondary market. Accordingly, investors will pay brokerage fees and/or transaction costs in connection with their dealings on stock exchange(s). These brokerage fees and/or transaction costs are not charged by, or payable to, the Sub-Fund nor the Management Company but to the investor own intermediary. In addition, the investors may also bear the costs of "bid-ask" spreads; meaning the difference between the prices at which shares can be bought and sold.

Primary Market: Authorized Participants dealing directly with the Fund will pay related primary market transaction costs.

## How long should I hold it and can I take money out early?

**Recommended holding period:** 5 years is based on our assessment of the risk and reward characteristics and costs of the Sub-Fund.

This product is designed for medium-term investment; you should be prepared to stay invested for at least 5 years. You can redeem your investment at any time, or hold the investment longer.

**Order Schedule:** Details of dealing frequency can be found under "What is this product?". Please see the "What are the costs?" section for details of any exit fees.

On the Primary Market the Company may:

- Suspend the redemption of shares, if exceptional circumstances so require, considering the interests of investors.
- Manage liquidity risks, by (i) limiting how many shares are redeemed in a short amount of time if redemption requests reach a predefined threshold beyond which such requests can no longer be executed in the best interests of all investors ("Gates"), and (ii) applying anti-dilution tools (anti-dilution levy or partial or full swing pricing) to mitigate material dilution for remaining investors.

On the Secondary Market, investors will generally be able to sell their shares on the relevant stock exchange. Further details can be found in the Prospectus.

## How can I complain?

If you have any complaints, you may:

- Call our complaints hotline on 01-4802000
- Mail Amundi Ireland Limited at One George's Quay Plaza, George's Quay, Dublin, Ireland
- E-mail to AILComplaints@amundi.com

In the case of a complaint you must clearly indicate your contact details (name, address, phone number or email address) and provide a brief explanation of your complaint. More information is available on our website [www.amundi.ie](http://www.amundi.ie).

If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

## Other Relevant Information

You may find the prospectus, constitutional documents, key investor documents, financial reports, and further information documents relating to the Sub-Fund including various published policies of the Sub-Fund on our website [www.amundi.ie](http://www.amundi.ie). You may also request a copy of such documents at the registered office of the Management Company.

Past performance: You can download the past performance of the Sub-Fund over the last 5 years at [www.amundi.ie](http://www.amundi.ie).

Performance scenarios: You can consult the previous performance scenarios updated each month on [www.amundi.ie](http://www.amundi.ie).